News and reporting on prostate cancer.
The number of technologies to be assessed is vast, and ranges from liquid biopsies and molecular imaging to immunohistochemistry and RNA-seq.
The company said it anticipates that more than 60 million Medicare beneficiaries will be covered for the ExoDx Prostate IntelliScore (EPI) test on Dec. 1.
The PCR-based test analyzes mitochondrial DNA to detect prostate cancer in advance of biopsy, independent of prostate-specific antigen levels and age.
The decision, which enables Medicare reimbursement, is effective for tests administered on or after Dec. 1.
Of the 29 companies in the index, 16 firms' share prices retreated while the other 13 saw their stock prices rise month over month.
Called the "Ccheck Prostate Cancer Confirmation" test, Anixa's assay integrates flow cytometry and machine learning to identify evidence of cancer in a person's bloodstream.
The study will evaluate how Prolaris impacts prostate cancer treatment decisions, and how those decisions impact costs within UK's National Health Service.
The Royal Oak, Michigan-based startup will use the funding to support development and commercialization of its pan-disease diagnostic testing platform.
For the six-month period ended June 30, the molecular diagnostic company's revenues fell to $10.9 million from $17.2 million in H1 2018.
Revenues were $226.4 million, down from $263.7 million for the same quarter last year, but above the Wall Street estimate of $225.6 million.